Even though ovarian cancer risk is lower with OC use, it stays elevated and timely risk-reducing BSO is recommended at the age of 40 years for BRCA1 and at the age of 45 years for BRCA2 mutation carriers. Here, BRCA1 is linked to ovarian carcinoma.